Abstract 3022: BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFbCDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML)

Abstract 3022: BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFbCDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML)

PTEFbCDK9 mediated transcription of short-lived anti-apoptotic survival proteins like Mcl-1 and Myc, plays a critical role in cancer cell growth and survival in various tumor entities including AML. In addition, these survival proteins exhibit important functions in the development of resistance to...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer research (Chicago, Ill.) Ill.), 2016-07, Vol.76 (14_Supplement), p.3022-3022
Hauptverfasser: Scholz, Arne, Oellerich, Thomas, Hussain, Akhtar, Lindner, Sarah, Luecking, Ulrich, Walter, Annette O, Ellinghaus, Peter, Valencia, Ray, von Nussbaum, Franz, Mumberg, Dominik, Brands, Michael, Ince, Stuart, Serve, Hubert, Ziegelbauer, Karl
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:PTEFbCDK9 mediated transcription of short-lived anti-apoptotic survival proteins like Mcl-1 and Myc, plays a critical role in cancer cell growth and survival in various tumor entities including AML. In addition, these survival proteins exhibit important functions in the development of resistance to chemotherapy.
ISSN:0008-5472
1538-7445
DOI:10.1158/1538-7445.AM2016-3022